Almost no one is neutral about the protective netting at Citi Field, which places many seats behind a barrier. Many appreciate the safeguards, while some complain it ruins the view.
NYS Entity Status
NYS Filing Date
JANUARY 08, 2013
NYS DOS ID#
NYS Entity Type
DOMESTIC BUSINESS CORPORATION
2013 - MANY & MANY INC.
AROUND THE WEB
- Eyesore or Blessing? New Safety Feature at Citi Field Divides Fans
By WALLACE MATTHEWS - Sunday Jul 23, 2017
- Robot Revolution: Amazon’s Move Signals End of Line for Many Cashiers
By CLAIRE CAIN MILLER - Saturday Jun 17, 2017
The next jobs set to disappear may be ones that are a bigger part of people’s daily lives: retail workers and cashiers in stores and restaurants.
- Uber’s C.E.O. Pick, Dara Khosrowshahi, Steps Into Brighter Spotlight
By DAVID STREITFELD and NELLIE BOWLES - Monday Aug 28, 2017
Mr. Khosrowshahi has many tasks ahead of him, including repairing Uber’s internal culture and preparing the company for a self-driving future.
- Ryder Trucks Launches Campaign With 'Inc.'
Tuesday Sep 19, 2017
"The campaign underscores how truck owners are essentially dumping cash all over America's highways from all the hidden costs required in maintaining a private fleet," Ryder's Karen Jones tells"Marketing Daily."
- DataCamp Nabs $4M for Data Science Courses, Moves to NY
By Jeff Engel - Thursday Jul 27, 2017
Data scientists remain in high demand. But these days, many types of professionals can boost their career prospects if they have at least a basic level of “data literacy,” says Jonathan Cornelissen. That’s part of the reason why he says his online education company, DataCamp, has been growing over the past couple of years. DataCamp, […]
- Abbvie’s hep C drug pricing threatens Gilead’s dominance
By Max Nisen - Tuesday Aug 8, 2017
Pharma already leads the business world in unpredictability, with billions in sales potentially riding on a few points of statistical significance in a clinical trial.[...] even within that context, a series of blockbuster medicines for hepatitis C have made for a roller-coaster ride for companies and investors.AbbVie Inc. last week threw another big curve at this market by pricing its newly FDA-approved drug Mavyret — which might be the most effective hepatitis C medicine approved yet — at a massive discount.Medicines from Johnson & Johnson, Merck & Co. Inc. and Vertex Pharmaceuticals Inc. approved within the past six years, which once booked billions in combined sales, are now essentially non-factors.After offering behind-the-scene discounts to insurance companies, pharmacy benefit managers and other payers, Mavyret’s price is actually not far from Harvoni’s, according to Bloomberg Intelligence.The real headache for Gilead — which already faces steep declines in hepatitis C drug sales because of increasing competition and the fact that many patients have been cured — lies in the fact that not all hepatitis patients or medicines are the same.AbbVie’s new drug can treat all of the major subtypes of hepatitis C. And it can cure the disease in many patients in just eight weeks.